MedTrace Logo

Prospective Cohort Study of Children With GSD1b Receiving Empagliflozin

NCT04986735 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2021-08-16

No results posted yet for this study

Summary

This is a prospective cohort study of children with GSD1b to evaluate their outcome after using empagliflozin for neutrophil defects.

Conditions

  • Glycogen Storage Disease Type IB

Interventions

DRUG

Empagliflozin

All subjects will have a baseline assessment and be prospectively followed up for 52 weeks to examine their outcome after receiving empagliflozin for neutropenia and neutrophil dysfunction.

Sponsors & Collaborators

  • Hong Kong Children's Hospital

    lead OTHER

Principal Investigators

  • Mei Kwun Kwok · Hong Kong Children's Hospital

Eligibility

Min Age
6 Months
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-08
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04986735 on ClinicalTrials.gov